[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2022012900A - Análogos de nucleósido espirocíclico para el tratamiento de la hepatitis e. - Google Patents

Análogos de nucleósido espirocíclico para el tratamiento de la hepatitis e.

Info

Publication number
MX2022012900A
MX2022012900A MX2022012900A MX2022012900A MX2022012900A MX 2022012900 A MX2022012900 A MX 2022012900A MX 2022012900 A MX2022012900 A MX 2022012900A MX 2022012900 A MX2022012900 A MX 2022012900A MX 2022012900 A MX2022012900 A MX 2022012900A
Authority
MX
Mexico
Prior art keywords
spirocyclic
hepatitis
treatment
nucleoside analogues
nucleoside
Prior art date
Application number
MX2022012900A
Other languages
English (en)
Inventor
Tim Hugo Maria Jonckers
Yannick Debing
Frederik Pauwels
Original Assignee
Janssen Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc filed Critical Janssen Pharmaceuticals Inc
Publication of MX2022012900A publication Critical patent/MX2022012900A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente descripción se dirige a análogos del nucleósido espirocíclico, composiciones que comprenden estos compuestos y su uso para tratar infecciones por hepatitis E.
MX2022012900A 2020-04-14 2021-04-13 Análogos de nucleósido espirocíclico para el tratamiento de la hepatitis e. MX2022012900A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20169495 2020-04-14
PCT/EP2021/059514 WO2021209427A1 (en) 2020-04-14 2021-04-13 Spirocyclic nucleoside analogues for the treatment of hepatitis e

Publications (1)

Publication Number Publication Date
MX2022012900A true MX2022012900A (es) 2023-01-24

Family

ID=70289608

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012900A MX2022012900A (es) 2020-04-14 2021-04-13 Análogos de nucleósido espirocíclico para el tratamiento de la hepatitis e.

Country Status (9)

Country Link
US (1) US20230201236A1 (es)
EP (1) EP4135716A1 (es)
JP (1) JP2023522612A (es)
CN (1) CN115443138A (es)
AU (1) AU2021255811A1 (es)
BR (1) BR112022020810A2 (es)
CA (1) CA3174825A1 (es)
MX (1) MX2022012900A (es)
WO (1) WO2021209427A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3027B1 (ar) * 2009-05-14 2016-09-05 Janssen Products Lp نيوكليوسيدات يوراسيل سبيرواوكسيتان
EP2638053B1 (en) * 2010-11-10 2016-08-31 Janssen Products, L.P. Uracyl spirooxetane nucleoside phosphoramidates
ES2531583T3 (es) * 2010-11-10 2015-03-17 Janssen Products, L.P. Fosforamidatos de espironucleósido oxetánico uracílico
WO2016069975A1 (en) * 2014-10-31 2016-05-06 Cocrystal Pharma, Inc. 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
WO2016178876A2 (en) * 2015-05-01 2016-11-10 Cocrystal Pharma, Inc. Nucleoside analogs for treatment of the flaviviridae family of viruses and cancer
US10307438B2 (en) * 2016-06-03 2019-06-04 Gilead Sciences, Inc. Methods of treating hepatitis E viral infection
LT3676276T (lt) * 2017-09-01 2022-01-10 Janssen Pharmaceutica Nv Spirotietano nukleozidai

Also Published As

Publication number Publication date
CA3174825A1 (en) 2021-10-21
BR112022020810A2 (pt) 2022-11-29
CN115443138A (zh) 2022-12-06
AU2021255811A1 (en) 2022-12-22
WO2021209427A1 (en) 2021-10-21
EP4135716A1 (en) 2023-02-22
JP2023522612A (ja) 2023-05-31
US20230201236A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
PH12020550531A1 (en) Novel, highly active pyrazolo-piperidine substituted indole2-carboxamides active against the hepatitis b virus (hbv)
GEP20257731B (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
MX2020006864A (es) Modalidades combinadas para inhibidores de nucleosidos y/o nadph oxidasa (nox) como agentes antivirales especificos de mieloides.
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
CR20220675A (es) Análogos de nucleósido de 1´- ciano y usos de los mismos
ZA202001717B (en) Compounds, salts thereof and methods for treatment of diseases
PH12018550150A1 (en) Elimination of hepatitis b virus with antiviral agents
GEP20237519B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
BR112018074395A2 (pt) derivados de pirazol como inibidores de calicreína plasmática
PH12022550033A1 (en) Compounds useful to treat influenza virus infections
PH12020550525A1 (en) Novel, highly active amino-thiazole substituted indole-2carboxamides active against the hepatitis b virus (hbv)
EA201992322A2 (ru) Соединения и композиции для лечения гематологических расстройств
ZA202201364B (en) Deuterated compounds for use in the treatment of cancer
PH12021550970A1 (en) 6,7-dihydro-4h-pyrazolo[1,5-a]pyrazine indole-2-carboxamides active against the hepatitis b virus (hbv)
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
CL2021001117A1 (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
MX2023004796A (es) Compuestos, composiciones y metodos de uso para tratar fracturas oseas.
BR112022001025A2 (pt) Inibidores de calicreína plasmática
PH12022552679A1 (en) Bi- and monocyclic nucleoside analogs for treatment of hepatitis e
AU2020353055A8 (en) Antiviral pyrazolopyridinone compounds
MX2022012900A (es) Análogos de nucleósido espirocíclico para el tratamiento de la hepatitis e.
JOP20190214A1 (ar) ثنائي هيدرو إيندين-?-كربوكساميدات ونظائر منها بها استبدال، وطرق تستخدمها
MX2021006993A (es) Analogos de nucleosidos de ciclopentilo como antivirales.
MX2022012901A (es) Análogos de nucleósido de alquinilo para el tratamiento de la hepatitis e.
PH12023551898A1 (en) Cyclic oxaphosphinane compounds and analogues thereof for treating fibrotic diseases